- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears ResolutionMD for Android Devices
Calgary Scientific Inc. has received FDA clearance for its software for diagnostic medical image viewing on Android mobile devices.
Calgary Scientific Inc. has received FDA clearance for its software for diagnostic medical image viewing on Android mobile devices.
ResolutionMD allows physicians to securely view patient images from computers and mobile devices, collaborate with practitioners, and make diagnoses in real time, according to the company. Patient information is not stored on the device. A 2012 Mayo Clinic study found that radiologists using ResolutionMD versus a PACS workstation accessed CT scans of stroke victims 24 percent faster, representing 11 minutes per patient, the company said.
Calgary Scientific is the first company to receive FDA clearance for diagnostic image viewing on a variety of Android devices, according to the company. ResolutionMD Web received FDA clearance in 2009, and in 2011 it was cleared for use on iPhone and iPad. ResolutionMD is also CE marked for distribution in Europe and licensed by Health Canada.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
